newsfilter
← Latest News
PR Newswire·

IM Cannabis Explores U.S. Market Entry Following President Trump's Executive Order on Increasing Medical Marijuana and Cannabidiol Research

  • IM Cannabis Corp. (Nasdaq: IMCC) is actively evaluating strategic opportunities to enter the U.S. cannabis market following President Donald Trump's December 18, 2025 executive order to expedite marijuana rescheduling from Schedule I to Schedule III.
  • The company has engaged SSC Advisors as exclusive financial advisors to guide its U.S. market entry strategy & assess potential divestitures of its German & Israeli operations.
  • SSC Advisors will provide strategic guidance on U.S. expansion, identify potential partners or acquirors, & manage transaction processes for the company's international assets.
  • IM Cannabis Corp. currently operates medical cannabis businesses in Israel through subsidiaries & online platforms, & in Germany through its subsidiary Adjupharm GmbH.
  • The company plans to monitor federal developments regarding the executive order & the subsequent rulemaking process while continuing to focus on sustainable growth in its existing markets.